MeiraGTx Holdings (MGTX) said Tuesday that data from a study of its experimental Parkinson's disease treatment, AAV-GAD, showed a statistically significant improvement in motor examination score in the high-dose group compared with no significant change in the sham or low-dose groups.
The drug also significantly improved the disease-specific, patient-reported quality of life measures in both the high and low-dose groups, with no substantial change in the sham group.
AAV-GAD was safe and well tolerated, with no serious adverse events reported.
The company plans to use the study's data for discussions with regulators in the US, Europe, and Japan to initiate a global Phase 3 study.
MeiraGTx shares jumped more than 12% in premarket trading.
Price: 5.2100, Change: +0.57, Percent Change: +12.28
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。